相关实验视频
Updated: Jul 13, 2025

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.3K
在心血管和脏疾病中的益生菌,益生菌和营养素
Zitong Lei1, Menglu Xu2, Ying Li3
1Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Nutrients
|October 14, 2023
概括
心血管疾病 (CVD) 和慢性病 (CKD) 显著影响全球健康. 这项研究探讨了它们的相互联系和对患者治疗结果的影响.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 公共卫生 公共卫生
背景情况:
- 心血管疾病 (CVD) 和慢性病 (CKD) 构成了全球重大健康挑战.
- 这些疾病是导致死亡的主要原因,并在全球范围内对整体健康负担作出重大贡献.
- 了解心血管疾病和CKD之间的相互作用对于有效的疾病管理至关重要.
研究的目的:
- 研究心血管疾病和慢性病之间的复杂关系.
- 确定共享的风险因素和病理生理机制.
- 探索潜在的治疗策略来管理并发性心血管疾病和CKD.
主要方法:
- 流行病学研究的系统审查.
- 对临床试验数据的分析.
- 在受影响人群中的生物标志物分析.
主要成果:
- 在CKD进展和心血管疾病风险增加之间发现了强烈的关联.
- 共同的危险因素包括高血压,糖尿病和炎症.
- 某些生物标志物表明,慢性病患者心血管风险增加.
结论:
- CKD是心血管疾病的一个独立风险因素.
- 针对共同风险因素的综合管理策略至关重要.
- 需要进一步的研究来开发新型疗法用于并发性心血管疾病和CKD.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
24
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
24
Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Chronic Kidney Disease IV: Nursing Management
9
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
9
Chronic Kidney Disease I: Introduction
18
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
18
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441

